Literature DB >> 8466552

Characterization of cannabidiol-mediated cytochrome P450 inactivation.

L M Bornheim1, E T Everhart, J Li, M A Correia.   

Abstract

Cannibidiol (CBD) has been shown to impair hepatic drug metabolism in several animal species and to markedly inhibit mouse hepatic microsomal delta 1-tetrahydrocannabinol (THC) metabolism by inactivating specific cytochrome P450s (P450) belonging to the 2C and 3A subfamilies. Elucidation of the mechanism of CBD-mediated P450 inhibition would be clinically very important for predicting its effect on metabolism of THC and the many other clinically important drugs known to be metabolized by P450s 2C and 3A. CBD-mediated inactivation of mouse hepatic microsomal P450s did not decrease hepatic microsomal heme content. However, [14C]CBD was found covalently bound to microsomal protein in an approximately equimolar ratio to P450 loss. Immunoprecipitation of microsomal protein with antibodies raised against either P450 2C or 3A revealed that approximately equal amounts of [14C]-CBD were bound to each of these P450s after CBD-mediated inactivation. Furthermore, this specific P450 binding was equivalent to P450 loss and accounted for nearly all of the microsomal [14C]CBD irreversible binding. Although > 80% of the enzyme activities attributed to P450s 2C and 3A were inactivated by CBD at the anticonvulsant dose of 120 mg/kg, P450 2C was approximately 3-fold more sensitive than P450 3A at the lower CBD doses tested. CBD analogs were synthesized in order to elucidate the chemical pathways for CBD-mediated P450 inactivation in vivo. Oxidations at allylic carbon positions or saturation of either the exocyclic double bond or both double bonds of the terpene moiety did not markedly affect the inhibitory properties of the analogs. Methylation of both phenolic groups of the resorcinol moiety completely blocked the P450-inhibitory properties of this analog, revealing the involvement of a free hydroxyl group in the inactivation process. Rotation of the resorcinol moiety in abnormal-CBD did not impair the inhibitory properties of the analog, suggesting that the position of the hydroxyl group relative to the terpene ring is unimportant. Further studies are required to fully understand the chemical basis of CBD-mediated P450 inactivation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8466552     DOI: 10.1016/0006-2952(93)90286-6

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  10 in total

Review 1.  The Endocannabinoid System and its Modulation by Phytocannabinoids.

Authors:  Vincenzo Di Marzo; Fabiana Piscitelli
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 2.  Cannabidiol and Cannabinoid Compounds as Potential Strategies for Treating Parkinson's Disease and L-DOPA-Induced Dyskinesia.

Authors:  Nilson Carlos Ferreira Junior; Maurício Dos-Santos-Pereira; Francisco Silveira Guimarães; Elaine Del Bel
Journal:  Neurotox Res       Date:  2019-10-22       Impact factor: 3.911

3.  Interactions between THC and cannabidiol in mouse models of cannabinoid activity.

Authors:  S A Varvel; J L Wiley; R Yang; D T Bridgen; K Long; A H Lichtman; B R Martin
Journal:  Psychopharmacology (Berl)       Date:  2006-03-30       Impact factor: 4.530

4.  Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol.

Authors:  Robert E Vann; Thomas F Gamage; Jonathan A Warner; Ericka M Marshall; Nathan L Taylor; Billy R Martin; Jenny L Wiley
Journal:  Drug Alcohol Depend       Date:  2008-04-01       Impact factor: 4.492

Review 5.  Cannabinoids and Epilepsy.

Authors:  Evan C Rosenberg; Richard W Tsien; Benjamin J Whalley; Orrin Devinsky
Journal:  Neurotherapeutics       Date:  2015-10       Impact factor: 7.620

Review 6.  "Natural" is not synonymous with "Safe": Toxicity of natural products alone and in combination with pharmaceutical agents.

Authors:  Tyler E Gaston; Donna L Mendrick; Mary F Paine; Amy L Roe; Catherine K Yeung
Journal:  Regul Toxicol Pharmacol       Date:  2020-03-18       Impact factor: 3.271

7.  Synthetic, non-intoxicating 8,9-dihydrocannabidiol for the mitigation of seizures.

Authors:  Mark Mascal; Nema Hafezi; Deping Wang; Yuhan Hu; Gessica Serra; Mark L Dallas; Jeremy P E Spencer
Journal:  Sci Rep       Date:  2019-05-23       Impact factor: 4.379

8.  Nonlinear Disposition and Metabolic Interactions of Cannabidiol Through CYP3A Inhibition In Vivo in Rats.

Authors:  Michiru Nagao; Yukako Nakano; Masataka Tajima; Erika Sugiyama; Vilasinee Hirunpanich Sato; Makoto Inada; Hitoshi Sato
Journal:  Cannabis Cannabinoid Res       Date:  2020-12-15

Review 9.  The endocannabinoid system and sex steroid hormone-dependent cancers.

Authors:  Thangesweran Ayakannu; Anthony H Taylor; Timothy H Marczylo; Jonathon M Willets; Justin C Konje
Journal:  Int J Endocrinol       Date:  2013-11-27       Impact factor: 3.257

Review 10.  Human Metabolites of Cannabidiol: A Review on Their Formation, Biological Activity, and Relevance in Therapy.

Authors:  István Ujváry; Lumír Hanuš
Journal:  Cannabis Cannabinoid Res       Date:  2016-03-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.